化疗所致血小板减少症治疗的研究进展

doi:10.11904/j.issn.1002-3070.2016.02.020

摘要/Abstract

摘要： 化疗所致血小板减少症(Chemotherapy-induced thrombocytopenia,CIT)是常见的化疗药物剂量限制性毒性反应,可能导致化疗药物剂量降低或化疗时间延迟,甚至可能导致出血事件发生。输注血小板是治疗CIT的基本方法。促血小板生长因子的出现,如重组人白介素-11(Recombinant human interleukin-11,rhIL-11)、重组人血小板生成素(Recombinant human thrombopoietin,rhTPO)和血小板生成素受体激动剂(Thrombopoietin receptor agonist,TPO-RA),为我们提供了方便有效的治疗策略。其它一些因子和近端脾动脉栓塞术(Proximal splenic artery embolization,PSAE)有可能成为新的治疗药物或方法。本文就CIT治疗的研究进展进行综述。

关键词: 化疗, 血小板减少症, 治疗

Abstract: Chemotherapy induced thrombocytopenia(CIT)is a major dose-limiting hematologic toxicity with cancer patients.Aside from bleeding risk,thrombocytopenia limits chemotherapy doses and frequencies.While platelet transfusion is remain the elementary method for CIT,administration of platelet growth factors,such as recombinant human interleukin-11(rhIL-11),recombinant human thrombopoietin(rhTPO)and thrombopoietin receptor agonist(TPO-RA),are convenient and effective platelet-support strategies for patients receiving myelosuppressive chemotherapy.In addition,other cytokines and proximal splenic artery embolization(PSAE)are expected to be new clinical therapies.In this review,we summarize the existing data and approaches in the treatment progress of CIT.

Key words: Chemotherapy, Thrombocytopenia, Treatment

中图分类号:

R733.7

孙国强综述, 孙立春审校. 化疗所致血小板减少症治疗的研究进展[J]. 实用肿瘤学杂志, 2016, 30(2): 184-188.

SUN Guoqiang, SUN Lichun. Treatment progress of chemotherapy induced thrombocytopenia[J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(2): 184-188.

参考文献

1 Ten Berg MJ,van den Bemt PM,Shantakumar S,et al.Thrombocytopenia in adult cancer patients receiving cytotoxic chemotherapy:results from a retrospective hospital-based cohort study[J].Drug Saf,2011,34(12):1151-1160.
2 Piatek C,Akhtari M.Thrombocytopenia:optimizing approaches in cancer patients[J].Oncology(Williston Park),2015,29(4):297-298.
3 Chinese Society of Clinical Oncology.Expert consensus on diagnosis and treatment of chemotherapy-induced thrombocytopenia in cancer patients(2014 version)[J].Zhonghua Zhong Liu Za Zhi,2014,36(11):876-879.
4 Hitron A,Steinke D,Sutphin S,et al.Incidence and risk factors of clinically significant chemotherapy-induced thrombocytopenia in patients with solid tumors[J].J Oncol Pharm Pract,2011,17(4):312-319.
5 Tanriverdi O.Association of helicobacter pylori infection with chemotherapy-induced thrombocytopenia in patients with stage III colon cancer:a pilot study[J].Platelets,2014,25(2):118-124.
6 Tanriverdi O.Is there a predictive significance of ABO blood group on chemotherapy-induced thrombocytopenia in patients with stage III colon cancer?[J].Med Oncol,2015,32(1):384-391.
7 Stanworth SJ,Estcourt LJ,Powter G,et al.A no-prophylaxis platelet-transfusion strategy for hematologic cancers[J].N Engl J Med,2013,368(19):1771-1780.
8 Crighton GL,Estcourt LJ,Wood EM,et al.A therapeutic-only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation[J].Cochrane Database Syst Rev,2015,25(9):343-349.
9 Wandt H,Schaefer-Eckart K,Wendelin K,et al.Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies:an open-label,multicentre,randomised study[J].Lancet,2012,380(9850):1309-1316.
10 Kumar A,Mhaskar R,Grossman BJ,et al.Platelet transfusion:a systematic review of the clinical evidence[J].Transfusion,2015,55(5):1116-1127.
11 Nahirniak S,Slichter SJ,Tanael S,et al.Guidance on platelet transfusion for patients with hypoproliferative thrombocytopenia[J].Transfus Med Rev,2015,29(1):3-13.
12 Estcourt LJ,Stanworth SJ,Doree C,et al.Comparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation[J].Cochrane Database Syst Rev,2015,26(11):423-431.
13 Stanworth SJ,Hudson CL,Estcourt LJ,et al.Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies:recurrent event analysis[J].Haematologica,2015,100(6):740-747.
14 Slichter SJ,Kaufman RM,Assmann SF,et al.Dose of prophylactic platelet transfusions and prevention of hemorrhage[J].N Engl J Med,2010,362(7):600-613.
15 Estcourt LJ,Stanworth S,Doree C,et al.Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation[J].Cochrane Database Syst Rev,2015,32(10):632-642.
16 Kaushansky K.Use of thrombopoietic growth factors in acute leukemia[J].Leukemia,2000,14(3):505-508.
17 Tepler I,Elias L,Smith JW,et al.A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy[J].Blood,1996,87(9):3607-3614.
18 Jung Y,Ahn H,Kim DS,et al.Improvement of biological and pharmacokinetic features of human interleukin-11 by site-directed mutagenesis[J].Biochem Biophys Res Commun,2011,405(3):399-404.
19 Wu SK,Zhang Y,Xu LY,et al.Multicenter,randomized study of genetically modified recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in cancer patients receiving chemotherapy[J].Support Care Cancer,2012,20(8):1875-1884.
20 Dams-Kozlowska H,Kwiatkowska-Borowczyk E,Gryska K,et al.Designer cytokine hyper interleukin 11(H11)is a megakaryopoietic factor[J].Int J Med Sci,2013,10(9):1157-1165.
21 Li JZ,Yang C,Xia YP,et al.Thrombocytopenia caused by the development of antibodies to thrombopoietin[J].Blood,2001,98(12):3241-3248.
22 Kuter DJ.Managing thrombocytopenia associated with cancer chemotherapy[J].Oncology(Williston Park),2015,29(4):282-294.
23 Vadhan-Raj S,Verschraegen CF,Bueso-Ramos C,et al.Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer[J].Ann Intern Med,2000,132(5):364-368.
24 Erickson-Miller CL,Pillarisetti K,Kirchner J,et al.Low or undetectable TPO receptor expression in malignant tissue and cell lines derived from breast,lung,and ovarian tumors[J].BMC Cancer,2012,12:405.
25 Parameswaran R,Lunning M,Mantha S,et al.Romiplostim for management of chemotherapy-induced thrombocytopenia[J].Support Care Cancer,2014,22(5):1217-1222.
26 Demeter J,Istenes I,Fodor A,et al.Efficacy of romiplostim in the treatment of chemotherapy induced thrombocytopenia(CIT)in a patient with mantle cell lymphoma[J].Pathol Oncol Res,2011,17(1):141-143.
27 Berthelot-Richer M,Boilard B,Morin A,et al.Romiplostim efficacy in an acute myeloid leukemia patient with transfusion refractory thrombocytopenia[J].Transfusion,2012,52(4):739-741.
28 Winer ES,Safran H,Karaszewska B,et al.Eltrombopag with gemcitabine-based chemotherapy in patients with advanced solid tumors:a randomized phase I study[J].Cancer Med,2015,4(1):16-26.
29 García Lagunar MH,Cerezuela Fuentes P,Martínez Penella M,et al.Experience of off-label use of eltrombopag in the treatment of thrombocytopenia associated with solid tumors[J].Farm Hosp,2015,39(3):157-160.
30 Ghanima W,Lee SY,Barsam S,et al.Venous thromboembolism and coagulation activity in patients with immune thrombocytopenia treated with thrombopoietin receptor agonists[J].Br J Haematol,2012,158(6):811-814.
31 Moulis G,Bagheri H,Sailler L,et al.Are adverse drug reaction patterns different between romiplostim and eltrombopag? 2009-2013 French PharmacoVigilance assessment[J].Eur J Intern Med,2014,25(8):777-780.
32 Mitchell WB,Bussel JB.Thrombopoietin receptor agonists:a critical review[J].Semin Hematol,2015,52(1):46-52.
33 Holl P,Lisá L,Plameňová I,et al.Recombinant activated factor VII as an additional agent in the management of bleeding in patients with chemotherapy-induced thrombocytopenia[J].Blood Transfus,2013,11(3):466-468.
34 Zhan L,Zhang YL,Feng Z,et al.Recombinant human tyrosyl-tRNA synthetase,a novel thrombopoietic agent[J].Eur J Pharmacol,2014,738(6):293-300.
35 Bhatia SS,Venkat S,Echenique A,et al.Proximal splenic artery embolization in chemotherapy-induced thrombocytopenia:a retrospective analysis of 13 patients[J].J Vasc Interv Radiol,2015,26(8):1205-1211.

[1]	侯玉雪,李晓莉. Wnt7a与恶性肿瘤的关系及研究进展[J]. 实用肿瘤学杂志, 2019, 33(3): 271-275.
[2]	朱琳,张春霞. 纳米载药系统靶向肿瘤干细胞的研究进展[J]. 实用肿瘤学杂志, 2019, 33(3): 276-279.
[3]	李珊,赵春波,乔文波. 术中放疗在胰腺癌中的应用进展[J]. 实用肿瘤学杂志, 2019, 33(3): 280-283.
[4]	冯越,邢丽楠,王棹,张云艳. NLR与肿瘤同步放化疗预后的相关性研究[J]. 实用肿瘤学杂志, 2019, 33(3): 284-288.
[5]	梁虹, 李奇, 王耀先, 靳红, 王铜, 王亚楠, 段雅妮, 宋敏. 宫颈癌化疗心血管毒性预防的间断时间序列试验[J]. 实用肿瘤学杂志, 2019, 33(2): 134-138.
[6]	马志杰, 王帆, 赵亚双. 乳腺癌化疗患者生存质量及影响因素分析[J]. 实用肿瘤学杂志, 2019, 33(2): 149-154.
[7]	秦岚群, 邹征云. 恶性黑色素瘤化疗研究进展[J]. 实用肿瘤学杂志, 2019, 33(2): 167-172.
[8]	方琳, 刘超, 张纯慧, 张艳桥. 转移性结直肠癌维持治疗的研究现状与治疗策略[J]. 实用肿瘤学杂志, 2019, 33(2): 173-178.
[9]	常晓霞综述, 宋冰冰, 刘家仁审校. 植物化学物增加肿瘤细胞对化疗药物敏感性的研究进展[J]. 实用肿瘤学杂志, 2019, 33(1): 67-72.
[10]	丁界先, 张津, 陈永刚, 王兴文综述, 王栓科审校. Wnt信号通路与肿瘤发生的研究进展[J]. 实用肿瘤学杂志, 2019, 33(1): 73-77.
[11]	邢志超综述, 麦威审校. 脂肪肉瘤潜在作用靶点的研究进展[J]. 实用肿瘤学杂志, 2019, 33(1): 82-86.
[12]	张攀, 张迪综述, 戴晓波审校. 复发鼻咽癌再程放射治疗的研究进展[J]. 实用肿瘤学杂志, 2019, 33(1): 92-96.
[13]	田洋, 吴华星. 超细鼻胃镜在消化道狭窄性疾病中的临床应用[J]. 实用肿瘤学杂志, 2018, 32(6): 550-554.
[14]	李悦, 徐可, 韩增祥, 孙敏, 樊国华综述, 张勇审校. 结肠癌中肿瘤相关巨噬细胞的作用及靶向治疗的研究进展[J]. 实用肿瘤学杂志, 2018, 32(5): 450-454.
[15]	王元综述, 孙轶华审校. β-连环蛋白在软组织肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2018, 32(5): 455-459.